Related Experiment Video
Updated: Jul 5, 2025

10:12
Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
Published on: September 19, 2022
2.1K
Engineered Peptides Harboring Cation Motifs Against Multidrug-Resistant Bacteria
Lu Shang1,2, Chan Chen1,2, Rui Sun1,2
1Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China.
ACS Applied Materials & Interfaces
|January 24, 2024
Summary
New short antimicrobial peptides (AMPs) show high activity against multidrug-resistant (MDR) bacteria and biofilms. The peptide KLR effectively treats sepsis in animal models, offering a promising new agent for combating drug-resistant infections.
Area of Science:
- Biochemistry
- Microbiology
- Pharmacology
Background:
- Multidrug-resistant (MDR) pathogens present a significant global health threat.
- There is an urgent need for novel antimicrobial agents to combat resistant bacterial infections.
Purpose of the Study:
- To develop and characterize novel short antimicrobial peptides (AMPs) with a cation end motif.
- To evaluate the efficacy of these peptides against MDR bacteria, biofilms, and in an animal sepsis model.
Main Methods:
- Synthesis and characterization of nine amino acid peptides.
- Bioactivity assays against MDR planktonic bacteria and mature biofilms.
- Mechanistic studies involving reactive oxygen species accumulation and membrane disruption.
- In vivo efficacy testing in a murine model of sepsis.
Main Results:
- A peptide with a central "RWWWR" motif and "KXR" unit (KLR) demonstrated high activity against MDR planktonic bacteria.
- The peptide KLR achieved a 92.33% clearance rate against mature bacterial biofilms.
- Mechanistic studies revealed KLR induces excessive reactive oxygen species and disrupts bacterial membranes.
- KLR showed significant therapeutic effects in an animal model of sepsis caused by MDR bacteria.
Conclusions:
- The study identified a dominant structural motif for potent short antimicrobial peptides.
- The peptide KLR exhibits broad-spectrum activity and a dual mechanism of action against MDR bacteria.
- KLR represents a promising candidate for development as a new therapeutic agent against drug-resistant bacterial infections.

